^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Antioxidant

    Related drugs:
    5d
    Genetic and Physical Study of Childhood Nerve and Muscle Disorders (clinicaltrials.gov)
    P=N/A, N=2323, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting --> Active, not recruiting | N=9300 --> 2323
    Enrollment closed • Enrollment change
    9d
    MAVEN: MitoQ to Improve Vascular Funciton in Preeclampsia (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting | Initiation date: Dec 2025 --> Mar 2026
    Enrollment open • Trial initiation date
    10d
    Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke (clinicaltrials.gov)
    P2, N=300, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    12d
    A Study on the Effects of A2 Milk on Gut Beneficial Bacteria Growth and Digestion Improvement (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Seoul National University Bundang Hospital | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    IL4 (Interleukin 4)
    13d
    ANti-Oxidant in Variant Angina (ANOVA) Trial (clinicaltrials.gov)
    P4, N=320, Terminated, Seoul National University Hospital | Unknown status --> Terminated; The study was terminated early due to slow recruitment and the Principal Investigator's retirement.
    Trial termination
    |
    atorvastatin
    16d
    MitoQ for Fatigue in Multiple Sclerosis (MS) (clinicaltrials.gov)
    P1/2, N=45, Completed, VA Office of Research and Development | Active, not recruiting --> Completed
    Trial completion
    18d
    A Randomized Controlled Trial of Idebenone for Cognitive Impairment in Cerebral Small Vessel Disease (ChiCTR2600119095)
    P=N/A, N=158, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New trial
    18d
    Research on ROS-responsive nanocarriers for targeted delivery of the PICK1 plasmid to synergistically improve sepsis-induced coagulopathy through combined anti-inflammatory and antioxidant effects (ChiCTR2600117864)
    P=N/A, N=75, Taizhou Hospital of Zhejiang Province; Taizhou Hospital of Zhejiang Province
    New trial
    19d
    Effects of interleukin-18 on CD4+PD-1+ T cells may contribute to the pathogenesis of immune thrombocytopenia (PubMed, Sheng Li Xue Bao)
    This cytokine secretion promoting effect of IL-18 was inhibited by the ROS scavenger MitoQ...Under IL-18 stimulation, the sPD-1 level in the supernatant of healthy control CD4+ T cell culture was significantly increased. These results suggest that IL-18 may affect the function of CD4+PD-1+ T cells by regulating the production of mitochondrial ROS, and participate in their immune regulation through PD-1 pathway, thereby contributing to the pathogenesis of ITP.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator) • IL18 (Interleukin 18) • CD40LG (CD40 ligand)
    21d
    Cisplatin-induced renal toxicity: an integrated view of molecular pathways and emerging therapeutic targets-a comprehensive review. (PubMed, Toxicol Mech Methods)
    Compounds such as MitoQ, ferrostatin-1, necrostatin-1, and NLRP3 inhibitors have demonstrated promising effects in preclinical models by attenuating cisplatin-induced renal damage. Overall, this review highlights the need for individualized, multi-targeted strategies to prevent and manage cisplatin-induced nephrotoxicity by integrating mechanistic insights, clinical challenges, and emerging therapeutic advances. Such approaches may improve cancer treatment outcomes while preserving renal function.
    Review • Journal
    |
    IL18 (Interleukin 18) • KIM1 (Kidney injury molecule 1) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    cisplatin
    26d
    NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, Nacuity Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    27d
    INCA: PK and PD Study of NPI-001 and Cysteamine Bitartrate (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Nacuity Pharmaceuticals, Inc. | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date